Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis

Stuart SchlossmanMS Drug Therapies, Pediatric MS

Sep 13, 2018
  • Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a
  • MS severely affects the everyday lives of children and adolescents with the disease and carries a significant impact throughout their lifetime
  • Gilenya, a leading oral therapy for relapsing MS, is the only treatment approved by the US FDA for patients from 10 years of age through to adulthood 
CONTINUE reading the complete detail 

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

To receive MS news and information via e-mail, Please Click here 
                     
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews